Literature DB >> 6369202

[Isolated liver perfusion in advanced metastases of colorectal cancers].

K R Aigner, H Walther, J C Tonn, K H Link, P Schoch, K Schwemmle.   

Abstract

A special cannulation system was developed in order to completely isolate the liver in an extracorporeal circuit. Isolated hyperthermic liver perfusion at 40 degrees C with an average dosage of 1000 mg 5-FU was performed in 32 patients with liver metastases (29 colorectal carcinomas, 2 carcinoids, 1 primary hepatoma). 12 patients who had an overall 45% tumor invasion of the entire liver-volume as measured in CT-scan were treated exclusively by isolated liver perfusion. In that group median survival was 8 months and death occurred in the presence of extrahepatic metastases. Better results are achieved with isolated liver perfusion followed by intraarterial short-time infusions (Mitomycin C/5-FU) via an Implantofix catheter. Median actual survival in this group is 12 months, the longest follow-up period is 23 months.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6369202     DOI: 10.1159/000215394

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  4 in total

1.  Rationale and indications for perfusion in liver tumors: current data.

Authors:  K Schwemmle; K H Link; B Rieck
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

2.  Low dose intraarterial cis-platinum/radiotherapy after local tumour preradiation.

Authors:  H Wieler; H W Hoffmanns; A Kippels; S Huhndorf; A Düx
Journal:  Radiat Environ Biophys       Date:  1987       Impact factor: 1.925

3.  True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Carlo Ori; Federico Innocente; Romano Scalerta; Mauro Ceccherini; Pier Paolo Da Pian; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

4.  Leukocyte activation by isolated hyperthermic liver and limb perfusion due to malignancy.

Authors:  J P Arnestad; A Bengtsson; J P Bengtson; L Hafström; H Redl; G Schlag
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.